Supplemental References

1. Trembizki E, Guy R, Donovan B, et al. Further evidence to support the individualised treatment of gonorrhoea with ciprofloxacin. Lancet Infect Dis. 2016; 16:1005-1006.
2. Lahra MM, Trembizki E, Buckley C, et al. Changes in the rates of Neisseria gonorrhoeae antimicrobial resistance are primarily driven by dynamic fluctuations in common gonococcal genotypes. J Antimicrob Chemother. 2017; 72:705-711.
3. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03):1-137.
4. PHAC. Canadian Guidelines on Sexually Transmitted Infections – Gonococcal Infections Chapter. Public Health Agency of Canada, Ottawa, 2013.
5. Perry C, Dumont E, Perry C, Raychaudhuri A. A phase II, randomised, study in adult subjects evaluating the efficacy, safety, and tolerability of single doses of gepotidacin (GSK2140944) for treatment of uncomplicated urogenital gonorrhoea. Sex Transm Infect 2017; 93(Suppl 2):A11.
6. Scangarella-Oman N, Hossain M, Dixon P, et al. Microbiological analysis from a phase ii study in adults evaluating single doses of gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea caused by neisseria gonorrhoeae. Sex Transm Infect 2017; 93(Suppl 2):A84.
7. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011; 55:3538-45.
8. Gulati S, Zheng B, Reed GW, et al. Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection. PLoS Pathog. 2013; 9:e1003559.
9. Earle SG, Wu CH, Charlesworth J, et al. Identifying lineage effects when controlling for population structure improves power in bacterial association studies. Nat Microbiol 2016; 1:16041.
10. Petousis-Harris H, Paynter J, Morgan J, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017; 390:1603-1610.